Home › Companies › Ionis Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Ionis Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-08 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Ionis Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Ionis Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-08 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Spencer R. Berthelsen | 119,824,353 | 20,816,547 | 98,115 | -- | 12,305,695 | Majority: yes |
| Elect Director: Joan E. Herman | 135,599,646 | 5,076,895 | 62,474 | -- | 12,305,695 | Majority: yes |
| Proposal 2: An advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of the named executive officers, as | 135,537,973 | 5,088,105 | 112,937 | -- | 12,305,695 | Majority: yes |
| Proposal 3: Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc | 108,377,084 | 32,303,288 | 58,643 | -- | 12,305,695 | Majority: yes |
| Proposal 4: Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under such plan by 750,000 shares and to remove the termination date of the plan: | 140,348,001 | 332,204 | 58,810 | -- | 12,305,695 | Majority: yes |
| Proposal 5: Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year: | 148,893,646 | 4,000,539 | 150,525 | -- | 0 | Majority: yes |
Source: Ionis Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-08 — read the filing on EDGAR.
Each item below shows how the 482 asset managers that disclosed a Ionis Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Ionis Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 8 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Ionis Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: An advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensat”): 135,537,973 for, 5,088,105 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 165,262,556 outstanding shares: 82% for, 3% against (85% of the company cast a for/against vote).
The 480 asset managers below cast 97% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 41,473,473 | 165 | 0 | 0 | For |
| Capital Group | 36,850,986 | 0 | 0 | 0 | For |
| Vanguard | 20,694,693 | 11 | 0 | 0 | For |
| T. Rowe Price | 14,461,093 | 0 | 0 | 0 | For |
| BlackRock | 8,078,205 | 0 | 0 | 0 | For |
| Wellington | 5,622,981 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 4,723,802 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,980,754 | 0 | 0 | 0 | For |
| State Street | 3,180,170 | 3,841 | 0 | 0 | For |
| Charles Schwab | 3,121,572 | 0 | 0 | 0 | For |
| American Century | 2,638,895 | 0 | 0 | 0 | For |
| RBC Global Asset Management (U.S.) Inc. | 2,322,181 | 0 | 0 | 0 | For |
| Tweedy, Browne Co LLC | 2,158,924 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1,979,669 | 0 | 0 | 0 | For |
| TWEEDY, BROWNE FUND INC. | 1,963,162 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 1,748,458 | 0 | 0 | 0 | For |
| Artisan | 1,693,539 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 1,567,672 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 1,565,932 | 0 | 0 | 0 | For |
| Invesco | 0 | 1,404,928 | 0 | 0 | Against |
| PICTET ASSET MANAGEMENT SA | 1,318,567 | 0 | 0 | 0 | For |
| JPMorgan | 1,296,917 | 0 | 0 | 0 | For |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 1,096,374 | 0 | 0 | 0 | For |
| Jackson National | 831,772 | 150,988 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 867,805 | 0 | 0 | Against |
Showing the 25 largest of 480 asset managers. See all 480 in the interactive database.
Combines 4 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Ionis Pharmaceuticals, Inc.’s own tally for this item (“Proposal 4: Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under such plan by 750,000 shares and to remove the ”): 140,348,001 for, 332,204 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 165,262,556 outstanding shares: 85% for, 0.3% against (85% of the company cast a for/against vote).
The 122 asset managers below cast 99.9% of the shares they voted on this item FOR (83,838,470 for, 1,765 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,414,476 | 1 | 0 | 0 | For |
| Fidelity | 17,072,170 | 0 | 0 | 0 | For |
| Capital Group | 15,689,002 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,306,307 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 4,723,802 | 0 | 0 | 0 | For |
| BlackRock | 3,679,155 | 0 | 0 | 0 | For |
| TWEEDY, BROWNE FUND INC. | 1,963,162 | 0 | 0 | 0 | For |
| Charles Schwab | 1,536,094 | 0 | 0 | 0 | For |
| State Street | 1,308,413 | 0 | 0 | 0 | For |
| JPMorgan | 1,296,917 | 0 | 0 | 0 | For |
| American Century | 1,275,849 | 0 | 0 | 0 | For |
| Jackson National | 982,760 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 800,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 598,636 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 594,587 | 0 | 0 | 0 | For |
| MFS | 573,889 | 0 | 0 | 0 | For |
| Invesco | 546,518 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 498,800 | 0 | 0 | 0 | For |
| TIAA | 459,061 | 0 | 0 | 0 | For |
| First Trust | 411,205 | 0 | 0 | 0 | For |
| Neuberger Berman | 350,745 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 347,272 | 0 | 0 | 0 | For |
| Goldman Sachs | 341,791 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 333,637 | 0 | 0 | 0 | For |
| ARK ETF Trust | 269,786 | 0 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.
Combines 2 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Ionis Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc”): 108,377,084 for, 32,303,288 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 165,262,556 outstanding shares: 66% for, 20% against (85% of the company cast a for/against vote).
The 117 asset managers below cast 83% of the shares they voted on this item FOR (69,359,616 for, 13,792,761 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,414,371 | 105 | 0 | 0 | For |
| Fidelity | 3,494,139 | 13,578,031 | 0 | 0 | Against |
| Capital Group | 15,689,002 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,306,307 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 4,723,802 | 0 | 0 | 0 | For |
| BlackRock | 3,679,155 | 0 | 0 | 0 | For |
| TWEEDY, BROWNE FUND INC. | 1,963,162 | 0 | 0 | 0 | For |
| Charles Schwab | 1,536,094 | 0 | 0 | 0 | For |
| State Street | 1,308,400 | 13 | 0 | 0 | For |
| JPMorgan | 1,296,917 | 0 | 0 | 0 | For |
| American Century | 1,275,849 | 0 | 0 | 0 | For |
| Jackson National | 982,760 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 800,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 598,636 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 594,587 | 0 | 0 | 0 | For |
| MFS | 573,889 | 0 | 0 | 0 | For |
| Invesco | 546,518 | 0 | 0 | 0 | For |
| TIAA | 459,061 | 0 | 0 | 0 | For |
| First Trust | 411,205 | 0 | 0 | 0 | For |
| Neuberger Berman | 350,745 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 347,272 | 0 | 0 | 0 | For |
| Goldman Sachs | 341,791 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 333,637 | 0 | 0 | 0 | For |
| ARK ETF Trust | 269,786 | 0 | 0 | 0 | For |
| MassMutual | 258,430 | 0 | 0 | 0 | For |
Showing the 25 largest of 117 asset managers. See all 117 in the interactive database.
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Ionis Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Joan E. Herman”): 135,599,646 for, 5,076,895 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 165,262,556 outstanding shares: 82% for, 3% against (85% of the company cast a for/against vote).
The 116 asset managers below cast 97% of the shares they voted on this item FOR (81,012,934 for, 2,283,538 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,414,463 | 14 | 0 | 0 | For |
| Fidelity | 17,072,170 | 0 | 0 | 0 | For |
| Capital Group | 15,689,002 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,173,586 | 2,132,721 | 0 | 0 | For |
| NEW ECONOMY FUND | 4,723,802 | 0 | 0 | 0 | For |
| BlackRock | 3,679,155 | 0 | 0 | 0 | For |
| TWEEDY, BROWNE FUND INC. | 1,963,162 | 0 | 0 | 0 | For |
| Charles Schwab | 1,536,094 | 0 | 0 | 0 | For |
| State Street | 1,308,413 | 0 | 0 | 0 | For |
| JPMorgan | 1,296,917 | 0 | 0 | 0 | For |
| American Century | 1,275,849 | 0 | 0 | 0 | For |
| Jackson National | 982,760 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 800,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 598,636 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 594,587 | 0 | 0 | 0 | For |
| MFS | 573,889 | 0 | 0 | 0 | For |
| Invesco | 546,518 | 0 | 0 | 0 | For |
| TIAA | 459,061 | 0 | 0 | 0 | For |
| First Trust | 411,205 | 0 | 0 | 0 | For |
| Neuberger Berman | 350,745 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 347,272 | 0 | 0 | 0 | For |
| Goldman Sachs | 341,791 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 333,637 | 0 | 0 | 0 | For |
| ARK ETF Trust | 269,786 | 0 | 0 | 0 | For |
| MassMutual | 258,430 | 0 | 0 | 0 | For |
Showing the 25 largest of 116 asset managers. See all 116 in the interactive database.
Combines 5 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Ionis Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Spencer R. Berthelsen”): 119,824,353 for, 20,816,547 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 165,262,556 outstanding shares: 73% for, 13% against (85% of the company cast a for/against vote).
The 116 asset managers below cast 90% of the shares they voted on this item FOR (74,662,443 for, 8,634,029 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,403,967 | 10,510 | 0 | 0 | For |
| Fidelity | 17,072,170 | 0 | 0 | 0 | For |
| Capital Group | 15,689,002 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 5,306,307 | 0 | 0 | Against |
| NEW ECONOMY FUND | 4,723,802 | 0 | 0 | 0 | For |
| BlackRock | 3,679,155 | 0 | 0 | 0 | For |
| TWEEDY, BROWNE FUND INC. | 1,963,162 | 0 | 0 | 0 | For |
| Charles Schwab | 1,536,094 | 0 | 0 | 0 | For |
| State Street | 4,038 | 1,304,375 | 0 | 0 | Against |
| JPMorgan | 1,296,917 | 0 | 0 | 0 | For |
| American Century | 1,275,849 | 0 | 0 | 0 | For |
| Jackson National | 490,004 | 492,756 | 0 | 0 | Against |
| Franklin Custodian Funds | 800,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 0 | 598,636 | 0 | 0 | Against |
| MUTUAL FUND SERIES TRUST | 594,587 | 0 | 0 | 0 | For |
| MFS | 573,889 | 0 | 0 | 0 | For |
| Invesco | 546,518 | 0 | 0 | 0 | For |
| TIAA | 459,061 | 0 | 0 | 0 | For |
| First Trust | 411,205 | 0 | 0 | 0 | For |
| Neuberger Berman | 350,745 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 347,272 | 0 | 0 | 0 | For |
| Goldman Sachs | 341,791 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 333,637 | 0 | 0 | 0 | For |
| ARK ETF Trust | 269,786 | 0 | 0 | 0 | For |
| MassMutual | 8,419 | 250,011 | 0 | 0 | Against |
Showing the 25 largest of 116 asset managers. See all 116 in the interactive database.
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Ionis Pharmaceuticals, Inc.’s own tally for this item (“Proposal 5: Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year:”): 148,893,646 for, 4,000,539 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 165,262,556 outstanding shares: 90% for, 2% against (93% of the company cast a for/against vote).
The 116 asset managers below cast 99.9% of the shares they voted on this item FOR (83,278,408 for, 18,064 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,404,026 | 10,451 | 0 | 0 | For |
| Fidelity | 17,072,170 | 0 | 0 | 0 | For |
| Capital Group | 15,689,002 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,306,307 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 4,723,802 | 0 | 0 | 0 | For |
| BlackRock | 3,679,155 | 0 | 0 | 0 | For |
| TWEEDY, BROWNE FUND INC. | 1,963,162 | 0 | 0 | 0 | For |
| Charles Schwab | 1,536,094 | 0 | 0 | 0 | For |
| State Street | 1,308,364 | 49 | 0 | 0 | For |
| JPMorgan | 1,296,917 | 0 | 0 | 0 | For |
| American Century | 1,275,849 | 0 | 0 | 0 | For |
| Jackson National | 982,760 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 800,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 598,636 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 594,587 | 0 | 0 | 0 | For |
| MFS | 573,889 | 0 | 0 | 0 | For |
| Invesco | 546,518 | 0 | 0 | 0 | For |
| TIAA | 459,061 | 0 | 0 | 0 | For |
| First Trust | 411,205 | 0 | 0 | 0 | For |
| Neuberger Berman | 350,745 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 347,272 | 0 | 0 | 0 | For |
| Goldman Sachs | 341,791 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 333,637 | 0 | 0 | 0 | For |
| ARK ETF Trust | 269,786 | 0 | 0 | 0 | For |
| MassMutual | 258,430 | 0 | 0 | 0 | For |
Showing the 25 largest of 116 asset managers. See all 116 in the interactive database.
99.7% Majority: yes · of votes cast
Ionis Pharmaceuticals, Inc.’s own tally for this item (“Proposal 4: Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under such plan by 750,000 shares and to remove the ”): 140,348,001 for, 332,204 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 165,262,556 outstanding shares: 85% for, 0.3% against (85% of the company cast a for/against vote).
The 5 asset managers below cast 99.2% of the shares they voted on this item FOR (649,919 for, 4,839 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Eversept Partners, LP | 498,800 | 0 | 0 | 0 | For |
| Brighthouse | 76,854 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 71,800 | 0 | 0 | 0 | For |
| VALUED ADVISERS TRUST | 0 | 4,839 | 0 | 0 | Against |
| FORUM FUNDS | 2,465 | 0 | 0 | 0 | For |
Ranked by the number of Ionis Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 165,262,556 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 25.10% |
| 2 | Capital Group | 22.30% |
| 3 | Vanguard | 12.52% |
| 4 | T. Rowe Price | 8.75% |
| 5 | BlackRock | 4.89% |
| 6 | Wellington | 3.40% |
| 7 | NEW ECONOMY FUND | 2.86% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.41% |
| 9 | State Street | 1.93% |
| 10 | Charles Schwab | 1.89% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 14.86% | 13F |
| FMR LLC | 13.02% | DEF14A |
| Capital World Investors | 12.82% | 13G |
| Vanguard Group | 9.95% | 13F |
| BlackRock | 6.32% | 13F |
| Two Sigma | 3.54% | 13F |
| State Street | 2.42% | 13F |
| T. Rowe Price | 1.83% | 13F |
| JPMorgan Chase | 1.43% | 13F |
| Goldman Sachs | 1.03% | 13F |
Percentages above are of 165,262,556 shares outstanding, as reported by Ionis Pharmaceuticals, Inc. on its Form 10-Q dated 2026-04-23 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Ionis Pharmaceuticals, Inc.’s 10-Q dated 2026-04-23. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Ionis Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-04, in the 2025-2026 proxy season, 482 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,300 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To make an advisory vote on executive compensation. — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Ionis Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-08.
Ionis Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).